
Opinion|Videos|May 8, 2024
Impact of the Introduction of Bispecifics on the Management of Multiple Myeloma
Ke Ning, MD, discusses the impact of the introduction of bispecific antibodies for treating patients with relapsed or refractory multiple myeloma.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Trump Executive Order Recommends Separating MMR Into 3 Shots
2
The Inflation Reduction Act and Oncology Drug Pricing: What Pharmacists Need to Know
3
Suzetrigine-Based Multimodal Therapy Enables Opioid-Free Recovery in Patients Receiving Surgery
4
FDA Fast Tracks First-in-Class TNFR2 Antibody as Chemotherapy-Free Strategy for Platinum-Resistant Ovarian Cancer
5






































































































